Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion

European Journal of Ophthalmology

Volumn 22, Issue 6, 2012, Pages 1013-1018

  Daien, Vincent ^a,b   Navarre, Sophie ^a   Fesler, Pierre ^c   Vergely, Laurence ^d   Villain, Max ^a   Schneider, Christelle ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b INSERM   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Bevacizumab; Central retinal vein occlusion; Predictive factors; Visual acuity

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; EYE INFECTION; EYE INFLAMMATION; FEMALE; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LETTER; MALE; MEAN MACULAR THICKNESS; NEOVASCULAR GLAUCOMA; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA TEAR; SCORING SYSTEM; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84866260803     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000162     Document Type: Article

References (27)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-41, discussion 141-3.
2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-7.
3. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 2010; 20: 402-9.
4. Spandau UHM, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2006; 84: 555-6.
5. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence to-mography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-9.
6. Hung KH, Lee SM, Lee SY, Lee FL, Yang CS. Intravitreal bevacizumab (Avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther 2010; 26: 85-90.
7. Rensch F, Jonas JB, Spandau UHM. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2009; 87: 77-81.
8. Algvere PV, Epstein D, von Wendt G, Seregard S, Kvanta A. Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 2011; 21: 789-95.
9. Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N. Bev-acizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol 2010; 20: 180-5.
10. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115: 47-54.
11. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased vi-sual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.
12. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-33.
13. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010; 150: 310-4.
14. Baseline and early natural history report The Central Vein Occlusion Study. Arch Ophthalmol 1993; 111: 1087-95.
15. Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 2010; 94: 1052-6.
16. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Le-long F, Samama MM. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996; 103: 551-60.
17. Hoeh AE, Ruppenstein M, Ach T, Dithmar S. OCT patterns of macular edema and response to bevacizumab therapyin retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1567-72.
18. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010; 248: 155-9.
19. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-91.
20. Ip MS, Scott IU, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-14.
21. Rensch F, Jonas JB, Spandau UHM. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2009; 87: 77-81.
22. DeCroos FC, Ehlers JP, Stinnett S, Fekrat S. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Curr Eye Res 2011; 36: 1164-70.
23. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
24. Hoeh AE, Ruppenstein M, Ach T, Dithmar S. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1567-72.
25. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008; 86: 925-7.
26. Kim NR, Chin HS. Progression of impending central retinal vein occlusion to the ischemic variant following intravitreal bevacizumab. Korean J Ophthalmol 2010; 24: 179-81.
27. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-9.